Sandra Waechter

470 total citations
18 papers, 292 citations indexed

About

Sandra Waechter is a scholar working on Hematology, Genetics and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Sandra Waechter has authored 18 papers receiving a total of 292 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Hematology, 5 papers in Genetics and 3 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Sandra Waechter's work include Iron Metabolism and Disorders (7 papers), Erythropoietin and Anemia Treatment (6 papers) and Hemoglobinopathies and Related Disorders (5 papers). Sandra Waechter is often cited by papers focused on Iron Metabolism and Disorders (7 papers), Erythropoietin and Anemia Treatment (6 papers) and Hemoglobinopathies and Related Disorders (5 papers). Sandra Waechter collaborates with scholars based in Switzerland, United States and Germany. Sandra Waechter's co-authors include Jan K. Buitelaar, Barbara Schäuble, Götz‐Erik Trott, Ute Richarz, Joris Berwaerts, L Szczepański, R. Sabatowski, Ronald L. Pisoni, Bruce Robinson and Murilo Guedes and has published in prestigious journals such as PLoS ONE, Scientific Reports and Journal of the American Society of Nephrology.

In The Last Decade

Sandra Waechter

16 papers receiving 282 citations

Peers

Sandra Waechter

HEMAT

PMH

APM

NEPHR

L. Teillet France

Masayo Ogawa Japan

Sevim Baybaş Türkiye

Jiejiao Zheng China

M. M. C. Uiterwijk Netherlands

Wen‐Yu Hsu Taiwan

Dimitri Markov United States

Anna Julia Krupa Poland

Solerte Sb Italy

Heikki Paatero Finland

L. Teillet France

Sandra Waechter

6 ×0.1

HEMAT

29 ×0.5

82 ×1.5

PMH

3 ×0.1

APM

26 ×0.5

NEPHR

Citations per year, relative to Sandra Waechter Sandra Waechter (= 1×) peers L. Teillet

Countries citing papers authored by Sandra Waechter

Since Specialization

Citations

This map shows the geographic impact of Sandra Waechter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Waechter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Waechter more than expected).

Fields of papers citing papers by Sandra Waechter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Waechter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Waechter. The network helps show where Sandra Waechter may publish in the future.

Co-authorship network of co-authors of Sandra Waechter

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Waechter. A scholar is included among the top collaborators of Sandra Waechter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Waechter. Sandra Waechter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Waechter, Sandra, et al.. (2025). Smartwatches in the Assessment of Heart Failure Patients in Epidemiology and Pathophysiology Studies: A Scoping Review. ESC Heart Failure. 12(3). 1727–1738. 1 indexed citations

Kelepouris, Ellie, et al.. (2025). Collaborative Management of Hyperkalemia in Patients with Complex Heart Failure. Case Reports in Nephrology and Dialysis. 15(1). 47–52.

Tene, Lilac, Avraham Karasik, Gabriel Chodick, et al.. (2023). Iron deficiency and the effectiveness of the BNT162b2 vaccine for SARS-CoV-2 infection: A retrospective, longitudinal analysis of real-world data. PLoS ONE. 18(5). e0285606–e0285606. 3 indexed citations

Guedes, Murilo, Daniel G. Muenz, Jarcy Zee, et al.. (2021). Serum Biomarkers of Iron Stores Are Associated with Increased Risk of All-Cause Mortality and Cardiovascular Events in Nondialysis CKD Patients, with or without Anemia. Journal of the American Society of Nephrology. 32(8). 2020–2030. 45 indexed citations

Lopes, Marcelo Barreto, Charlotte Tu, Jarcy Zee, et al.. (2021). A real-world longitudinal study of anemia management in non-dialysis-dependent chronic kidney disease patients: a multinational analysis of CKDopps. Scientific Reports. 11(1). 1784–1784. 26 indexed citations

Guedes, Murilo, Daniel G. Muenz, Jarcy Zee, et al.. (2021). Serum biomarkers of iron stores are associated with worse physical health-related quality of life in nondialysis-dependent chronic kidney disease patients with or without anemia. Nephrology Dialysis Transplantation. 36(9). 1694–1703. 22 indexed citations

Filippatos, Gerasimos, Piotr Ponikowski, Dimitrios Farmakis, et al.. (2021). Efficacy of intravenous ferric carboxymaltose in patients with acute heart failure and iron deficiency with and without anaemia: a subgroup analysis of AFFIRM-AHF. European Heart Journal. 42(Supplement_1). 1 indexed citations

Macdougall, Iain C., Ewa A. Jankowska, Marco Metra, et al.. (2021). FC 021EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. Nephrology Dialysis Transplantation. 36(Supplement_1). 1 indexed citations

Jankowska, Ewa A., Peter van der Meer, Marco Metra, et al.. (2021). Efficacy of intravenous ferric carboxymaltose for iron deficiency following acute heart failure (AHF) in patients with previously diagnosed HF: a subgroup analysis of AFFIRM-AHF. European Heart Journal Acute Cardiovascular Care. 10(Supplement_1). 1 indexed citations

10.

Karaboyas, Angelo, Hal Morgenstern, Sandra Waechter, et al.. (2019). Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period. Clinical Kidney Journal. 13(3). 425–433. 15 indexed citations

11.

Varannes, Stanislas Bruley des, et al.. (2013). On-Demand Proton Pump Inhibitory Treatment in Overweight/Obese Patients with Gastroesophageal Reflux Disease: Are There Pharmacodynamic Arguments for Using Higher Doses?. Digestion. 88(1). 56–63. 5 indexed citations

12.

Richarz, Ute, et al.. (2012). Sustained Safety and Efficacy of Once‐Daily Hydromorphone Extended‐Release (OROS^® hydromorphone ER) Compared with Twice‐Daily Oxycodone Controlled‐Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain. Pain Practice. 13(1). 30–40. 15 indexed citations

13.

Buitelaar, Jan K., Esther Sobanski, Rolf‐Dieter Stieglitz, et al.. (2012). Predictors of Placebo Response in Adults With Attention-Deficit/Hyperactivity Disorder. The Journal of Clinical Psychiatry. 73(8). 1097–1102. 20 indexed citations

14.

Buitelaar, Jan K., et al.. (2011). Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. The International Journal of Neuropsychopharmacology. 15(1). 1–13. 88 indexed citations

15.

Vojtaššák, J, et al.. (2011). A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee. Pain Research and Treatment. 2011. 1–9. 16 indexed citations

16.

Szczepański, L, et al.. (2010). A Randomized Study to Demonstrate Noninferiority of Once-Daily OROS® Hydromorphone with Twice-Daily Sustained-Release Oxycodone for Moderate to Severe Chronic Noncancer Pain. Pain Practice. 10(5). 404–415. 32 indexed citations

17.

Buitelaar, Jan K., et al.. (2010). P.1.c.025 Longterm safety and efficacy outcomes in adults with ADHD treated with prolonged-release methylphenidate. European Neuropsychopharmacology. 20. S249–S249.

18.

Waechter, Sandra, et al.. (2006). 711 DOUBLE‐BLIND, PLACEBO‐CONTROLLED, REPEAT‐DOSE ASSESSMENT OF ONCE‐DAILY OROS® HYDROMORPHONE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OSTEOARTHRITIS PAIN. European Journal of Pain. 10(S1). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact